Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs): Acceptability ‐ total dropouts
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) Dropouts due to any cause (acceptability) · people with cancer and depression It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty). Antidepressants for the treatment of depression in people with cancer (2023) · Cochrane Headline outcomes only | RR 0.83 [0.53, 1.3] | 3 studies · 237 participants | Very low |
Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) Dropouts due to any cause (acceptability) · patients with cancer and depression It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty). Antidepressants for the treatment of depression in people with cancer (2018) · Cochrane Headline outcomes onlyearlier version CD011006.PUB3, superseded | RR 0.83 [0.53, 1.3] | 3 studies · 237 participants | Very low |
Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) Acceptability ‐ dropouts due to any cause · patients with cancer and depression It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes acceptability ‐ dropouts due to any cause compared with tricyclic antidepressants (TCAs) (very low certainty). Antidepressants for the treatment of depression in people with cancer (2015) · Cochrane Headline outcomes onlyearlier version CD011006.PUB2, superseded | RR 0.83 [0.53, 1.3] | 3 studies · 237 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.